0001062993-22-023351.txt : 20221205 0001062993-22-023351.hdr.sgml : 20221205 20221205180545 ACCESSION NUMBER: 0001062993-22-023351 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221202 FILED AS OF DATE: 20221205 DATE AS OF CHANGE: 20221205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HALPERN JOHN D CENTRAL INDEX KEY: 0001234950 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 221446110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eterna Therapeutics Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10355 SCIENCE CENTER DRIVE STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 10355 SCIENCE CENTER DRIVE STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. DATE OF NAME CHANGE: 20210325 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-12-02 1 0000748592 Eterna Therapeutics Inc. ERNA 0001234950 HALPERN JOHN D PO BOX 540 PORTSMOUTH NH 03802 0 0 1 0 Common Stock 205 D Common Stock 2022-12-02 4 P 0 335920 3.28 A 450961 I As trustee of family trust Warrants (Right to Purchase) 3.28 2022-12-02 4 P 0 671840 0.125 A 2023-06-02 2028-12-02 Common Stock 671840 671840 I As trustee of family trust Reflects a 1-for-20 reverse stock split effective October 17, 2022. Held by John D. Halpern Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit. The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any. The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation. /s/ John D. Halpern 2022-12-05 /s/ Katherine H. Halpern 2022-12-05